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Objective: To develop and validate a responsive and
feasible ultrasound inflammation score for rheumatoid
arthritis (RA).
Methods: We used data from cohorts of early RA
(development) and established RA starting/switching
biologic therapy (validation). 4 tendons and 36 joints
were examined by a grey scale (GSUS) and power
Doppler semiquantitative ultrasound (PDUS) scoring
system (full score). Ultrasound score components were
selected based on factor analyses of 3-month change
in the development cohort. Responsiveness was
assessed by standardised response means (SRMs). We
assessed the proportion of information retained from
the full score by linear regression.
Results: 118 patients with early and 212 patients with
established RA were included. The final ultrasound score
included 8 joints (metacarpophalangeal 1–2–3, proximal
interphalangeal 2–3, radiocarpal, metatarsophalangeal
2–3) and 1 tendon (extensor carpi ulnaris) examined
bilaterally. The 6-month SRMs for the final score were
−1.24 (95% CI −1.47 to −1.02) for GSUS, and −1.09
(−1.25 to −0.92) for PDUS in early RA, with 87% of
total information retained for GSUS and 90% for PDUS.
The new score performed somewhat better than
formerly proposed scores in the validation cohort.
Conclusions: The Ultrasound in Rheumatoid Arthritis 9
joint/tendon score (USRA9) inflammation score showed
good responsiveness, retained most of the information
from the original full score and overall performed better
than previous scores in a validation cohort.
Trial registration numbers: NCT01205854,
ACTRN12610000284066; Post-results.
INTRODUCTION
Ultrasound (US) is increasingly used to
detect and monitor inflammation in
rheumatoid arthritis (RA), in clinical practice
and research. There is no agreement on
which joints and tendons should be assessed
for a sensitive, responsive and feasible US
measure of inflammation in RA.1
The research agenda proposed in recent
European League against Rheumatism
(EULAR) recommendations includes evalu-
ation of which joints should be assessed by
US.2 Several reduced joint scores for US
joint inflammation have been developed,
but, to the best of our knowledge, their
development has to a limited degree been
based on data-driven approaches.3–5
Our research group recently developed
two candidate sets of reduced US joint
inflammation scores in early RA through a
data-driven approach in cross-sectional data,
Key messages
What is already known about this subject?
▸ Ultrasound is increasingly used to detect and
monitor inflammation in rheumatoid arthritis.
What does this study add?
▸ By applying a data-driven process we have
developed the Ultrasound in Rheumatoid
Arthritis 9 joint/tendon score (USRA9), a feasible
and responsive reduced ultrasound inflammation
score for assessing rheumatoid arthritis, which
retains most of the information from a more
extensive examination.
How might this impact on clinical practice?
▸ This USRA9 score can be useful for monitoring
inflammation in rheumatoid arthritis.
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aiming to retain as much information as possible from
the full score.6 The candidate scores performed well in
a validation cohort of established RA, and performed
better than previously proposed reduced joint scores.3–5
Although these results showed that a reduced US assess-
ment might efficiently contribute to assessment in RA,
an US score has to be responsive in order to be an
important tool to monitor disease activity.
In the present study, longitudinal US data from the
ARCTIC trial, which became available after publication
of our previous paper, were used. The objective of the
current study was to develop a feasible US inflammation
score focusing on sensitivity to change, and to validate
the score by comparison with formerly proposed US
scores in an independent longitudinal cohort.
METHODS
Patient population
Patients (>18 years) with RA were included in one of two
cohorts between January 2010 and June 2013: early
disease-modifying antirheumatic drug (DMARD)-naïve
patients with RA fulfilling the 2010 American College of
Rheumatology (ACR)/EULAR classification criteria with
indication for methotrexate treatment (the ARCTIC
trial, ClinicalTrials.gov identifier NCT01205854), and
patients with established RA with active disease and indi-
cation for initiation of, or change of, biological DMARD
(the ULRABIT study, Anzctr.org.au identifier
ACTRN12610000284066).
Ultrasonography assessments
An extensive US examination was performed at baseline,
3 and 6 months by experienced sonographers using a
0–3 semiquantitative scoring system for grey-scale
(GSUS) and power Doppler US (PDUS) in each of the
following 36 joints and 4 tendons: metacarpophalangeal
(MCP) 1–5, proximal interphalangeal (PIP) 2–3, radio-
carpal, intercarpal, radioulnar, elbow, knee, talocrural,
metatarsophalangeal (MTP) 1–5, extensor carpi ulnaris
(ECU) tendon and tibialis posterior (TP) tendon bilat-
erally. The range of the sum scores was 0–120 for GSUS
and PDUS, and the scanning protocol was a slight modi-
fication of a previously published 32-joint protocol, with
the addition of bilateral PIP2–3, ECU and TP tendons.7
The scoring was performed with defined probe place-
ment and patient positioning and an US atlas as a refer-
ence.7 US workshops with static and dynamic hands-on
exercises to calibrate readers were arranged yearly.
We used Siemens Antares Sonoline or GE Logiq E9
machines with linear probes (11.4/13.0 MHz) and
power Doppler parameters were adjusted according to
the device used (pulse repetition frequency 391/
600 Hz; Doppler frequency 7.3/10.0 MHz) for US assess-
ments.8 There were no changes in US settings during
the study, and no upgrading of software.
Finally, we performed a substudy assessing the feasibil-
ity of the final Ultrasound in Rheumatoid Arthritis
9 joint/tendon score (USRA9) in clinical practice. Five
sonographers with experience in structured US assess-
ment were chosen, and recorded the time for bilateral
scanning and recording of the USRA9 score in 35 con-
secutive patients with polyarthritis.
Laboratory and clinical examinations
Assessments in both cohorts included erythrocyte sedi-
mentation rate (mm/hour), C reactive protein (mg/L),
anticyclic citrullinated peptide (IU/mL) and visual ana-
logue scales for investigator’s and patients global assess-
ments of disease activity (0–100 mm). In the early RA
cohort, 44-swollen joint count and Ritchie articular index
were performed, while 28 swollen and tender joint
counts were performed in the established RA cohort.9 10
Statistical analyses
We performed factor analyses of GSUS and PDUS
changes from baseline to 3 months (ΔGSUS and
ΔPDUS) in the early RA cohort to identify joint/tendon
groups with high internal correlation. The factor ana-
lyses were based on all joints/tendons examined in the
US protocol. We used the principal component method-
ology, with the factors rotated according to the varimax
criteria. The number of factors was based on eigenvalues
with a cut-off of 1. Based on these analyses, we identified
groups with correlating scores to guide the selection of
the final US joint set. In groups with more than one
joint identified by factor analysis, the selection process
was based on factor loading and previous work to iden-
tify joints that retained most information from the exten-
sive score.6 The final US score was defined as the sum of
the joint/tendon scores in the final joint set.
Second, standardised response means (SRMs; mean
change divided by the SD of the change) with 95% CIs
(by bootstrapping) were calculated at 3 and 6 months
for the final score and formerly proposed scores in the
early RA cohort. We also calculated 3 and 6 months
SRMs for the final score and previously proposed scores
in the validation cohort.
Finally, we assessed the proportion of total information
retained by the final score at baseline (both GSUS and
PDUS) using linear regression analyses with the total US
score (0–120) as the dependent variable and each indi-
vidual joint/tendon score in the final joint set as inde-
pendent variables. The proportion of information
retained was assessed using R2.
Statistical analyses were performed using SPSS (V.21
SPSS, Chicago, Illinois, USA), except for factor analyses
and bootstrapping, which were calculated in the SAS




In total, 118 DMARD-naïve patients with early RA with
indication for methotrexate and 212 patients with
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established RA with indication for starting or switching
biological DMARD were included. Baseline demo-
graphic and patient characteristics in the two cohorts
are presented in table 1. The 18 patients in the estab-
lished RA cohort who were in the Disease Activity
Score-28 (DAS28) remission had active arthritis in the
feet/ankles (n=15) or received intra-articular steroids
prior to inclusion (n=3).
Factor analyses
Based on the factor analyses for ΔGSUS and ΔPDUS, we
identified 12 joint groups, representing joints/tendons
with correlating scores (see online supplementary table
S1). Three groups (elbow, TP tendon and MTP1) were
characterised by small changes in GSUS and PDUS over
3 months and were excluded from the final candidate
score. In groups with multiple joints, the radiocarpal
joint, MCP3 and MTP3 were selected based on the
highest factor loading. Other groups were represented
by one joint or tendon which all was included in the
model (MCP1, MCP2, PIP2, PIP3, MTP2 and ECU
tendon). The final US inflammation score, named the
USRA9 score, is presented in figure 1.
Sensitivity to change of USRA9 compared with previously
proposed US scores
The USRA9 score displayed the same or better sensitivity
to change than our previous candidate sets and other
proposed reduced US scores for GSUS and PDUS at 3
and 6 months in the early RA cohort (figure 2A, B and
online supplementary table S2A, B).
Validation
In the validation cohort, the USRA9 score had the same
level or somewhat larger SRMs compared with our previ-
ous candidate sets and other US scores (figure 2C, D,
and online supplementary table S2C,D). The USRA9
Table 1 Baseline demographics and patient characteristics
Early RA (n=118) Established RA (n=212)
Age, years (mean (SD)) 50.6 (13.3) 51.9 (13.3)
Female sex (% (n)) 71.2 (84) 80.7 (171)
Positive anti-CCP (% (n)) 78.8 (93) 77.4 (164)
Disease duration, years (median (25–75 centile)) 0.5 (0.2–0.8)* 8.1 (2.9–14.7)†
Disease activity level‡ (% (n))
Remission 2.5 (3) 8.7 (18)
Low disease activity 12.7 (15) 7.3 (15)
Moderate disease activity 45.8 (54) 45.6 (94)
High disease activity 39.0 (46) 38.3 (79)
28-swollen joint count (median (25–75 centile)) 6 (3–11) 5 (2–10)
ESR, mm/hour (median (25–75 centile)) 18 (10–32) 25 (13–40)
CRP, mg/L (median (25–75 percentile)) 6 (3–15) 6 (2–15)
Investigator’s global assessment VAS (mean (SD)) 40.9 (20.1) 31.4 (16.4)
Patient’s global assessment VAS (mean (SD)) 51.9 (24.7) 50.3 (27.1)
Number of previously used synthetic DMARDs (mean (SD)) 0 2.1 (1.3)
Number of previously used biologic DMARDs (mean (SD)) 0 0.8 (1.1)
*From patient reported first swollen joint.
†From clinical diagnosis by rheumatologist.
‡Based on DAS level in the early RA and DAS28 level in the established RA cohort.
CCP, cyclic citrullinated peptide; CRP, C reactive protein; DAS28, Disease Activity Score-28; DMARD, disease-modifying antirheumatic drug;
ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; VAS, visual analogue scale.
Figure 1 The final ultrasound inflammation score (USRA9) for
rheumatoid arthritis. ( Included joints/tendon: MCP1, MCP2,
MCP3, PIP2, PIP3, radiocarpal joint, ECU tendon, MTP2 and
MTP3. All joints included in the USRA9 score are examined with
a longitudinal scan on the dorsal side. The extensor carpi ulnaris
tendon is examined in a longitudinal and transverse scan. All
joints and the tendon are scored 0–3 for GSUS (range 0–54)
and PDUS (range 0–54). Not included in the USRA9 (elbow
and knee were not included and are not shown). ECU, extensor
carpi ulnaris; GSUS, grey-scale ultrasound; MCP,
metacarpophalangeal; MTP, metatarsophalangeal; PDUS,
power Doppler ultrasound; PIP, proximal interphalangeal;
USRA9, Ultrasound in Rheumatoid Arthritis 9 joint/tendon score.
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score retained 87% of GSUS and 90% of PDUS informa-
tion from the full score (36 joints and 4 tendons) before
DMARD initiation in the early RA cohort. The corre-
sponding numbers in the established RA cohort were
90% for GSUS and 92% for PDUS (table 2). The
median (range) time to complete the USRA9 score bilat-
erally was 3 min 14 s (1 min 50 s to 5 min 53 s).
DISCUSSION
In this study, we present a feasible and responsive US
inflammation score for RA, the USRA9 score, which
includes examination of eight joints and one tendon.
The USRA9 score was selected based on factor analysis
of 3-month change in US scores in a recent longitudinal
cohort, as well as previous work to identify joints that
contribute the best information on inflammation in US
examination. Most of the information from an extensive
36 joints and 4 tendons score is retained, and the score
is more feasible than our previously proposed candidate
scores.6
Figure 2 SRMs at 3 and 6 months for the final ultrasound inflammation score (USRA9) bilaterally and previously proposed
scores (A) GSUS in the early RA cohort, (B) PDUS in the early RA cohort, (C) GSUS in the established RA cohort and (D)
PDUS in the established RA cohort. *SRMs (standardised response means); mean change divided by the SD of the change with
95% CIs. †Six-joint score Perricone et al:5 wrist, MCP2, knee bilaterally. ‡Seven-joint score Backhaus et al:4 wrist, MCP2, MCP3,
PIP2, PIP3, MTP2, MTP5 and extensor carpi ulnaris tendon dominant side. $Twelve-joint score Naredo et al:3 elbow, wrist,
MCP2, MCP3, knee, ankle and tibialis posterior tendon bilaterally. Final ultrasound inflammation score (USRA9): radiocarpal
joint, extensor carpi ulnaris tendon, MCP1, MCP2, MCP3, PIP2, PIP3, MTP2, MTP3. Dotted line indicating SRM value of most
responsive score. GSUS, grey-scale ultrasound; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PDUS, power Doppler
ultrasound; PIP, proximal interphalangeal; RA, rheumatoid arthritis; USRA9, Ultrasound in Rheumatoid Arthritis 9 joint/tendon
score.
Table 2 Proportion of information in the total ultrasound
score retained by the USRA9 score at baseline, assessed
by linear regression R2
Proportion of information in the
total US score retained by the






GSUS Unilateral‡ 0.70 0.79
Bilateral 0.87 0.90
PDUS Unilateral‡ 0.75 0.83
Bilateral 0.90 0.92
*Final US inflammation score (USRA9 score): MCP1, MCP2,
MCP3, PIP2, PIP3, radiocarpal joint, extensor carpi ulnaris
tendon, MTP2, MTP3.
†Linear regression analysis with the total US score at baseline as
dependent variable and each individual joint/tendon score of the
final joint set as independent variables.
‡Unilateral is dominant side.
GSUS, grey-scale ultrasound; MCP, metacarpophalangeal; MTP,
metatarsophalangeal; PDUS, power Doppler ultrasound; PIP,
proximal interphalangeal; RA, rheumatoid arthritis; US, ultrasound;
USRA9, Ultrasound in Rheumatoid Arthritis 9 joint/tendon score.
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Somewhat surprisingly, there were no substantial dif-
ferences in the SRMs between unilateral and bilateral
US examinations (see online supplementary table S1A,
B), and it is less time consuming to examine joints/
tendons only on one side of the body. The total informa-
tion retained was however higher if both sides were
examined (table 2), which is also supported by previous
studies indicating that RA is not necessarily a symmet-
rical disease.11 12 Unilateral examination of dominant
side may be sufficient in some settings, but our findings
indicate that a bilateral US joint/tendon examination
should be preferred.
Limitations of all synovial Doppler US grading systems
include the varying sensitivity of scanners and variable
US machine settings. In the present study, both the
machines and software were standardised between the
different centres, with no upgrade of software during
the follow-up. However, recent developments in the
hardware and software of US scanners may allow even
higher sensitivity to change, and computerised deter-
mination of the colour fraction may be more objective
than subjective estimation.13 Only dorsal examinations
of the joints were performed, thus we could not assess
the implications of applying different projections. The
study is strengthened by the validated semiquantitative
scoring system for GSUS and PDUS with high intra-rater
and inter-rater reliability, trained and calibrated sonogra-
phers, defined probe placements, availability of an US
atlas as reference, standardised equipment and an exten-
sive approach with two large independent cohorts of RA
where a substantial number of joints were examined.7 In
a substudy experienced sonographers familiar with the
inflammation score spent a median of just over 3 min to
perform bilateral scanning and recording of the USRA9
score. Our final US inflammation score includes many
of the same joints as in a previous study based on clin-
ical judgement and observed frequency of involvement
in mixed cohorts of RA.4 Feasibility of the final score is
improved compared with our previous candidate sets by
reducing the number of joints.
In conclusion, we have developed a feasible and
responsive reduced US inflammation score for RA,
retaining most of the information from an extensive
score, and which hopefully can contribute to a consen-
sual US inflammation score for RA. The final score can
be useful in clinical trials to assess US inflammation in
RA. The objective measure of joint inflammation pro-
vided by US gives unique opportunities to answer
research questions related to disease activity and inflam-
mation in RA.
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